Form 4: IDEXX Laboratories Director Daniel M. Junius Reports Stock Transactions
SEC Form 4 Filing
Director Daniel M. Junius reports exercising stock options and selling shares of IDEXX Laboratories on May 13, 2025.
Summary
- Daniel M. Junius, a director at IDEXX Laboratories, reported transactions involving the company's stock on May 13, 2025.
- He exercised non-qualified stock options to acquire 1,404 shares at $245.79 and 1,279 shares at $283.59.
- Following these transactions, he sold 2,683 shares at $506.4097.
- After these transactions, Junius directly owns 3,304 shares of IDEXX Laboratories.
- The options exercised were granted in 2020 and 2021 and vested one year after the grant date or on the date of the annual meeting of shareholders, whichever was earlier.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common among corporate executives and directors. These filings are monitored by investors to gain insights into management's perspective on the company's stock and future prospects.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The transactions reported are typical for executives who receive stock options as part of their compensation packages.
- Similar filings can be observed for executives at comparable companies in the veterinary diagnostics industry, such as Zoetis and Heska.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they provide insight into the director's view of the company's value.
- The impact on other stakeholders (employees, customers, suppliers, creditors) is likely negligible.
Key Dates
| Date | Description |
|---|---|
| 05/07/2029 | Expiration date of Non-Qualified Stock Option (right-to-buy) with exercise price of $245.79 |
| 05/05/2030 | Expiration date of Non-Qualified Stock Option (right-to-buy) with exercise price of $283.59 |
| 05/13/2025 | Date of earliest transaction: stock option exercise and sale of shares. |
| 05/14/2025 | Date of signature on the Form 4 filing. |
Keywords
IDEXX Laboratories, Director, Stock Options, Form 4, Insider Trading, Securities, Daniel M. Junius
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.